Achieve Life Sciences (ACHV)
NASDAQ:ACHV
Want to see ACHV full AI Analyst Report?
ACHV Stock Chart & Stats
$5.10
-$0.11(-3.08%)
At close: 4:00 PM EST
$5.10
-$0.11(-3.08%)
Day’s Range― - ―
52-Week Range$2.00 - $6.15
Previous CloseN/A
Volume131.37K
Average Volume (3M)1.29M
Market Cap
$566.68M
Enterprise Value$524.81M
Total Cash (Recent Filing)$29.27M
Total Debt (Recent Filing)$14.95M
Price to Earnings (P/E)―
Beta2.66
Next Earnings
Aug 06, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding102,659,060
10 Day Avg. Volume1,336,753
30 Day Avg. Volume1,285,943
Financial Highlights & Ratios
PEG Ratio-4.92
Price to Book (P/B)10.07
Price to Sales (P/S)0.00
P/FCF Ratio-4.38
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.16K
Enterprise Value/Ebitda-10.32
Forecast
1Y Price Target
$13.20Price Target Upside158.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Phase III Efficacy And TolerabilityConsistent, large Phase III efficacy—notably 32.4% vs 6% abstinence in hard-to-treat patients—establishes a clear clinical differentiation and durable adoption thesis for prescribers and payers. Strong tolerability data supports real-world adherence and a sustainable commercial uptake if approved.
Substantial Financing Improves RunwayA $180M upfront financing with up to $174M in milestone warrants materially reduces near-term funding risk, enabling NDA resubmission, manufacturing tech transfer and commercial launch planning. Backing from specialist healthcare investors also strengthens strategic execution capacity over the coming 2–6 months.
Durable IP And Onshore Manufacturing ProgressOnshoring drug product manufacturing with initial Adare batches reduces import/tariff and supply risks, while asserted IP protection into the 2030s–2040s supports a long-term franchise. Together these structural elements strengthen commercial defensibility and value capture post-approval.
Bears Say
Pre-commercial Cash Burn And No RevenueAchieve remains pre-commercial with persistent heavy cash burn (~$45.3M TTM) and no recurring product revenue, meaning ongoing reliance on external capital to fund operations. This structural cash-flow profile elevates financing risk and could constrain investment in launch and scale if capital markets tighten.
Rising Leverage As Equity ShrinksLeverage increased materially as equity declined, reducing financial flexibility and increasing refinancing risk. With stable absolute debt but a smaller equity base, the company faces less cushion for setbacks, making future fundraising more dilutive or costly and limiting strategic optionality ahead of commercialization.
Regulatory And Manufacturing Execution Risk (expected CRL)An anticipated FDA CRL tied to a third-party OAI forces a Q4 2026 resubmission and full tech transfer to Adare, creating durable execution risk. Uncertainty around resubmission class, transfer complexity and timing can delay approval, raise costs and compress the commercial launch window even with available financing.
Achieve Life Sciences News
ACHV FAQ
What was Achieve Life Sciences’s price range in the past 12 months?
Achieve Life Sciences lowest stock price was $2.00 and its highest was $6.15 in the past 12 months.
What is Achieve Life Sciences’s market cap?
Achieve Life Sciences’s market cap is $566.68M.
When is Achieve Life Sciences’s upcoming earnings report date?
Achieve Life Sciences’s upcoming earnings report date is Aug 06, 2026 which is in 54 days.
How were Achieve Life Sciences’s earnings last quarter?
Achieve Life Sciences released its earnings results on May 12, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.299 by $0.109.
Is Achieve Life Sciences overvalued?
According to Wall Street analysts Achieve Life Sciences’s price is currently Undervalued.
Does Achieve Life Sciences pay dividends?
Achieve Life Sciences does not currently pay dividends.
What is Achieve Life Sciences’s EPS estimate?
Achieve Life Sciences’s EPS estimate is -0.16.
How many shares outstanding does Achieve Life Sciences have?
Achieve Life Sciences has 102,659,060 shares outstanding.
What happened to Achieve Life Sciences’s price movement after its last earnings report?
Achieve Life Sciences reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.299. Following the earnings report the stock price went up 7.156%.
Which hedge fund is a major shareholder of Achieve Life Sciences?
Currently, no hedge funds are holding shares in ACHV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Achieve Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.20 (158.82% Upside)
$13.20 (158.82% Upside)
Blogger Sentiment
Bullish
ACHV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 42.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.62%
12-Months-Change
Fundamentals
Return on Equity
-193.49%
Trailing 12-Months
Asset Growth
21.01%
Trailing 12-Months
Company Description
Achieve Life Sciences
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
ACHV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: a substantial financing, experienced new leadership and commercial hires, U.S. manufacturing partnership with initial batches, robust Phase III efficacy (notably 32.4% vs 6% in hard-to-treat patients) and supportive mechanistic/tolerability data. The principal negatives are an anticipated FDA CRL tied to a third-party manufacturer OAI, requiring an NDA resubmission in Q4 2026 and introducing execution risk around the manufacturing tech transfer to Adare and timing uncertainty. Overall, the company appears well capitalized and operationally proactive to address the delays and pursue a planned H1 2027 launch, but near-term regulatory and manufacturing execution risks remain.View all ACHV earnings summariesACHV Stock 12 Month Forecast
Average Price Target
$13.20
▲(158.82% Upside)
Technical Analysis
Ownership Overview
0.87% Insiders
4.23% Mutual Funds
7.02% Other Institutional Investors
84.20% Public Companies and
Individual Investors